- Dr. Miguel Regueiro discusses recent advancements in IBD treatment, including promising results from clinical trials of drugs like guselkumab, risankizumab, and ustekinumab, particularly for perianal fistula management.
- Research on GLP-1 agonists, such as Ozempic, shows potential benefits for IBD patients, including reduced inflammation and improved gut health, alongside cardiovascular benefits.
- The studies presented at DDW 2024 emphasize the importance of personalized medicine and the potential for new therapeutic strategies to improve patient outcomes in IBD.
Keep Reading
Add A Comment